PC001- A Study to Evaluate the Usability of PointCheck
Phase NA Completed
81 enrolled
Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)
Completed
151 enrolled
Study to Compare the Efficacy and Safety of F-627 and GRAN®
Phase 3 Completed
242 enrolled 41 charts
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
Phase 1 Completed
59 enrolled
An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta®)
Completed
1,300 enrolled
Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Phase 1 Completed
18 enrolled 22 charts
Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Phase 3 Completed
393 enrolled 20 charts
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules
Completed
4,626 enrolled
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
Completed
361 enrolled
Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer
Phase 2 Completed
148 enrolled 45 charts
ADVANCE
Phase 3 Completed
406 enrolled 19 charts
SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide
Phase 3 Completed
237 enrolled 18 charts
Efficacy and Safety Study With MYL-1401H and Neulasta
Phase 3 Completed
193 enrolled
Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy
Phase 3 Completed
398 enrolled
A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
Phase 2 Completed
50 enrolled 39 charts
Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Phase 3 Completed
122 enrolled 19 charts
A Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients
Phase 3 Completed
143 enrolled
A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Phase 1/2 Completed
15 enrolled
Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients
Phase 2 Completed
80 enrolled
Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Phase 2 Completed
232 enrolled 19 charts
Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia
Phase 2 Completed
163 enrolled
Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy
Phase 2 Completed
80 enrolled
PLIANT
Phase 1/2 Completed
186 enrolled 12 charts
A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.
Phase 2 Completed
138 enrolled
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
Phase 3 Completed
847 enrolled 21 charts
Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer
Phase 2 Completed
34 enrolled 19 charts
PROTECT2
Phase 3 Completed
308 enrolled 19 charts
Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients
Phase 1 Completed
24 enrolled
PROTECT-1
Phase 3 Completed
316 enrolled 20 charts
Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)
Phase 4 Completed
75 enrolled 14 charts
Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)
Phase 3 Completed
602 enrolled
Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients
Phase 2 Completed
107 enrolled
Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer
Phase 2 Completed
60 enrolled 17 charts
Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients
Phase 3 Completed
135 enrolled 18 charts
Study on Efficacy and Safety of CBLB612 for Neutropenia Prophylaxis
Phase 2 Completed
23 enrolled
Evaluation of the Food Effect on the Safety, Tolerability, PK of EC-18 After Oral Administration in Healthy Volunteers
Phase 1 Completed
36 enrolled
Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers
Phase 1 Completed
64 enrolled
Safety and Efficacy Studies of rHSA/GCSF Fusion Protein For Injection to Treat Neutropenia
Phase 1 Completed
29 enrolled
PIONEER
Phase 3 Completed
218 enrolled 15 charts
Observational Study Investigating the Response Rate of Itraconazole Injection in Treating Immunocompromised Patients
Completed
438 enrolled
A Phase II Study Comparing Pegylated rhG-CSF(HHPG-19K) and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy
Phase 2 Completed
182 enrolled
Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma
Phase 2 Completed
77 enrolled
The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised Participants
Completed
203 enrolled 14 charts
Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy
Phase 3 Completed
928 enrolled
A Study of Empirical Antifungal Therapy With Itraconazole
Completed
138 enrolled
A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy
Phase 3 Completed
330 enrolled
Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia
Phase 2 Completed
189 enrolled
FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy
Phase 4 Completed
2,252 enrolled
A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
Phase 4 Completed
852 enrolled
Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy
Phase 2 Completed
44 enrolled